Suppr超能文献

巴西平价药品计划中的药品价格和可及性。

Medicine prices and availability in the Brazilian Popular Pharmacy Program.

机构信息

Escola Nacional de Saúde Pública Sergio Arouca, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brasil.

出版信息

Rev Saude Publica. 2010 Aug;44(4):611-9. doi: 10.1590/s0034-89102010005000021. Epub 2010 Jun 25.

Abstract

OBJECTIVE

To analyze the performance of the Programa Farmácia Popular do Brasil (FPB - Brazilian Popular Pharmacy Program) in the public and private sectors, in terms of availability and cost of medicines for hypertension and diabetes.

METHODS

The methodology developed by the World Health Organization, in partnership with the Health Action International, was used to compare medicines prices and availability. This study was performed in May 2007, in different sectors (public, private and the Program's government-managed [FPB-P] and private-sector-managed [FPB-E] categories), in 30 cities in Brazil. A total of four medicines were analyzed: captopril 25mg and hydrochlorothiazide 25mg for hypertension; and metformin 500mg and glibenclamide 5mg for diabetes.

RESULTS

FPB-E showed greatest medicine availability, while the public sector the lowest. The percentage of availability of similar medicines was higher than that of generic medicines, both in the public sector and in the FPB-P. Comparison of prices among sectors showed a lower purchase price in the FPB-E, followed by the FPB-P. The FPB-E charged prices that were over 90% cheaper than those in the private sector. The number of working days required to obtain treatment for hypertension and diabetes were fewer in the FPB-E.

CONCLUSIONS

The lower availability found in the public sector could be one of the reasons for the migration of users from the public sector to the FPB. The high prices in the private sector also contribute for this Program to be an alternative of medicine access in Brazil.

摘要

目的

分析巴西平价药品供应项目(FPB)在公共和私营部门在高血压和糖尿病药物的供应和成本方面的表现。

方法

本研究采用世界卫生组织与国际健康行动组织联合开发的方法,比较了药品价格和可及性。该研究于 2007 年 5 月在巴西 30 个城市的不同部门(公共部门、私营部门以及该项目的政府管理类别[FPB-P]和私营部门管理类别[FPB-E])进行。共分析了四种药物:卡托普利 25mg 和氢氯噻嗪 25mg 用于治疗高血压;以及二甲双胍 500mg 和格列本脲 5mg 用于治疗糖尿病。

结果

FPB-E 显示出最高的药物可及性,而公共部门的可及性最低。在公共部门和 FPB-P 中,类似药物的可及性百分比均高于仿制药。在各部门之间比较价格,FPB-E 的采购价格较低,其次是 FPB-P。FPB-E 的价格比私营部门便宜 90%以上。治疗高血压和糖尿病所需的工作天数在 FPB-E 中较少。

结论

公共部门较低的可及性可能是患者从公共部门转向 FPB 的原因之一。私营部门的高价格也促使该项目成为巴西获得药物的替代途径之一。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验